ICE Bioscience Inc., established in 2010 in Beijing, focuses on an integrated biological services platform for innovative drug discovery, encompassing target identification and validation, lead compound screening, optimization, and pre-clinical candidate stages. It pioneers an innovative CRO+ model in biological and pharmacological research technologies across oncology, immunology, cardiovascular, central nervous system, and metabolism diseases. ICE Bioscience is attuned to the needs of new drug development enterprises for quality, speed, efficiency, and cost, offering professional technical expertise and efficient communication to enhance the drug development process. It supports the national "industry-academia-research" strategy, bridging research, clinical, and commercial entities to provide comprehensive innovative biological technology support and cooperation.

ICE Bioscience's technical platforms include:

▪ Target-based drug screening platform: Established over 130 ion channel, more than 160 GPCR, over 1200 kinase and enzymatic targets, and over 40 nuclear receptor screening cell lines and validation methods. The company has independently purified more than 400 high-purity target proteins verified through activity tests, constructing over 500 drug-resistant strains, reporter systems, stable transfection, and gene-edited cell lines, covering most druggable targets.

▪ In vitro and in vivo pharmacology screening and evaluation platform: Includes oncology immunology, cardiovascular, and central nervous system pharmacodynamic evaluation based on cell, tissue, or animal models.

▪ DMPK and safety assessment platform: Includes ADME and PK studies, drug off-target effect screening (hERG, safety panel, kinase panel, etc.)

The company supports various drug screenings and biological services for small molecules, antibodies, ADCs, PROTACs, and small nucleic acids.

In 2022 and 2023, ICE Bioscience completed two funding rounds each exceeding one hundred million yuan. It has laboratories and business centers in Beijing, Shanghai, Xuzhou, Guiyang, Singapore, and Boston, with over 17,000 square meters of laboratory space, nearly 500 employees, and more than 150 million yuan invested in equipment. ICE Bioscience has established a strong technical team, with PhDs accounting for over 10% and masters or above over 45% of its staff. In 2023, the company completed its B+ funding round, continuously strengthening its digital and systematic construction, growing its staff to nearly 500.